

Manufacturers' Forum ANNOUNCEMENT

NorthStar HealthCare Consulting Georgia Department of Community Health

On behalf of the Georgia Department of Community Health (DCH) and in service to the Georgia Medicaid Fee-for-Service (FFS) Drug Utilization Review Board (DURB), NorthStar HealthCare Consulting (NHC), in conjunction with OptumRx, announces the Manufacturers' Forum for the January 2024 DURB meeting.

Date: Wednesday, December 13, 2023

Location: Floyd Building (Twin Towers)

2 Martin Luther King Jr. Drive, S.E.

19th Floor, MAP Conference Room (1952C)

East Tower, Atlanta, GA 30334

Appointments: The Manufacturers' Forum is by appointment only. Appointments may be requested after the Drugs Under Review document is posted to the DCH website at https://dch.georgia.gov/providers/provider-types/pharmacy/drug-utilization-review-board. Only manufacturers with drugs up for review at the upcoming DURB meeting will be granted appointments at this Forum. All requests for appointments must be made in writing to GAMedicaid@nhc-llc.com and include the drug name. New drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.

Guidelines for Participation:

- Individual manufacturer participation shall be limited to one 60-minute time segment per Forum. The
 presentation shall be limited to approximately 40 minutes with 20 minutes for questions and
 answers.
- An electronic <u>one-page</u> summary (front only, font 10, not including references) of each drug presentation, <u>factually based</u>, in a stand-alone, user-friendly document should be provided one week prior to the presentation via email to <u>GAMedicaid@nhc-Ilc.com</u>. Please include a pronunciation guide of the drug's brand and generic names. The one-page summary may be provided to the DURB members.

Helpful Information for Manufacturers with non-DURB Drugs:

- Manufacturers with new drugs that are not under review at the current DURB meeting are requested to wait until their drug is under review at a DURB meeting to request Forum participation.
- Manufacturers with new drugs that have orphan designation are highly encouraged to share any
 noteworthy information regarding their drug for review by DCH and NHC electronically. Please follow
 the one-page summary format described above and send to GAMedicaid@nhc-llc.com.
- Manufacturers seeking appointments for drugs that are currently listed on the Preferred Drug List (PDL) and/or the Providers' Administered Drug List (PADL) will be granted appointments at a future Forum or on an *ad hoc* basis at DCH/NHC's discretion. Regardless of whether an appointment is granted, all manufacturers are encouraged to send relevant, pertinent clinical information electronically to GAMedicaid@nhc-llc.com for our review. Please follow the one-page summary format described above.

Comments and Inquiries:

- Manufacturers with comments or inquiries related to Georgia Medicaid FFS <u>Preferred Drug List</u>, <u>Prior Authorization Criteria</u>, <u>Manufacturers' Forum or DURB</u> should submit these in writing to <u>GAMedicaid@nhc-llc.com</u>.
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS <u>claims processing</u> or drug benefit plan design should submit these in writing to <u>Tami.Sweat@optum.com</u>.
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS <u>supplemental rebates</u> should submit these in writing to <u>Georgia-DURB@magellanhealth.com</u>.